Discover
PCRX
Pacira BioSciences, Inc.
25.03
2 x 18.30
2 x 31.80
bid
ask
-
0.34
1.34%
2 @ 04:00 PM
25.44 +0.41 (1.64%)
| Ytd | -3.28% | |
| 1y | 7.66% |
24.59
day range
25.85
18.80
52 week range
27.64
| Open | 25.75 | Prev Close | 25.37 | Low | 24.59 | High | 25.85 | Mkt Cap | 984.88M |
| Vol | 543.14K | Avg Vol | 528.55K | EPS | 0.13 | P/E | 192.54 | Forward P/E | 6.87 |
| Beta | 0.20 | Short Ratio | 11.24 | Inst. Own | 118.81% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-30 | 50-d Avg | 23.69 | 200-d Avg | 23.41 | 1yr Est | 29.00 |
PCRX News
zacks.com
Pacira to Divest iovera Business to Zimmer Biomet in Up To $140M Deal
PCRX is set to sell its iovera franchise to ZBH in a deal worth up to $140M as it sharpens focus on
benzinga.com
HC Wainwright & Co. Reiterates Buy on Pacira BioSciences, Maintains $38 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Pacira BioSciences (NASDAQ:PCRX) with a B
benzinga.com
Pacira BioSciences Says UnitedHealthcare Now Provides Separate Reimbursement For EXPAREL Across Outp
-- Expands Patient Access to Non-Opioid Postsurgical Pain Management Across Outpatient Settings -- B
globenewswire.com
Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®
-- Expands Patient Access to Non-Opioid Postsurgical Pain Management Across Outpatient Settings --
benzinga.com
Pacira BioSciences Divests Iovera To Zimmer Biomet For Up To $140M
Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative
globenewswire.com
Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet
-- Pacira to receive up to $140 million with $70 million upfront and up to an additional $70 million